De Bruijn EA - Search Results

1

Vascular endothelial growth factor and angiogenesis.

Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Hoeben A, et al. Among authors: de bruijn ea. Pharmacol Rev. 2004 Dec;56(4):549-80. doi: 10.1124/pr.56.4.3. Pharmacol Rev. 2004. PMID: 15602010 Review.

2

Angiogenesis: possibilities for therapeutic interventions.

Wynendaele W, van Oosterom AT, Pawinski A, de Bruijn EA, Maes RA. Wynendaele W, et al. Among authors: de bruijn ea. Pharm World Sci. 1998 Dec;20(6):225-35. doi: 10.1023/a:1008600603059. Pharm World Sci. 1998. PMID: 9972522 Review.

3

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, van Oosterom AT. Wildiers H, et al. Among authors: de bruijn ea, de boeck g. Br J Cancer. 2003 Jun 16;88(12):1979-86. doi: 10.1038/sj.bjc.6601005. Br J Cancer. 2003. PMID: 12799646 Free PMC article.

4

The Nitrogen Mustards.

Highley MS, Landuyt B, Prenen H, Harper PG, De Bruijn EA. Highley MS, et al. Among authors: de bruijn ea. Pharmacol Rev. 2022 Jul;74(3):552-599. doi: 10.1124/pharmrev.120.000121. Pharmacol Rev. 2022. PMID: 35710137 Review.

5

Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?

Wynendaele W, Derua R, Hoylaerts MF, Pawinski A, Waelkens E, de Bruijn EA, Paridaens R, Merlevede W, van Oosterom AT. Wynendaele W, et al. Among authors: de bruijn ea. Ann Oncol. 1999 Aug;10(8):965-71. doi: 10.1023/a:1008377921886. Ann Oncol. 1999. PMID: 10509160 Free article. Clinical Trial.

6

Melphalan availability in hypoxia-inducible factor-1alpha+/+ and factor-1alpha-/- tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport.

Wildiers H, Guetens G, de Boeck G, Landuyt W, Verbeken E, Highley M, de Bruijn EA, van Oosterom AT. Wildiers H, et al. Among authors: de bruijn ea, de boeck g. Int J Cancer. 2002 Jun 1;99(4):514-9. doi: 10.1002/ijc.10391. Int J Cancer. 2002. PMID: 11992540

7

Pharmacology of anticancer drugs in the elderly population.

Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT. Wildiers H, et al. Among authors: de bruijn ea. Clin Pharmacokinet. 2003;42(14):1213-42. doi: 10.2165/00003088-200342140-00003. Clin Pharmacokinet. 2003. PMID: 14606930 Review.

8

Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry.

Guetens G, De Boeck G, Highley M, Dumez H, Van Oosterom AT, de Bruijn EA. Guetens G, et al. Among authors: de bruijn ea, de boeck g. J Chromatogr A. 2003 Dec 5;1020(1):27-34. doi: 10.1016/s0021-9673(03)00775-1. J Chromatogr A. 2003. PMID: 14661754

9

Unexpected interactions between nicotinamide and CPT-11 in a rhabdomyosarcoma tumor model.

Wildiers H, Ahmed B, Guetens G, De Boeck G, De Bruijn EA, Landuyt W, Van Oosterom AT. Wildiers H, et al. Among authors: de bruijn ea, de boeck g. Anticancer Res. 2003 Sep-Oct;23(5A):4055-9. Anticancer Res. 2003. PMID: 14666718

10

The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment.

Dumez H, Guetens G, De Boeck G, Highley MS, Maes RA, van Oosterom AT, de Bruijn EA. Dumez H, et al. Among authors: de bruijn ea, de boeck g. Clin Chem Lab Med. 2004;42(11):1219-27. doi: 10.1515/CCLM.2004.244. Clin Chem Lab Med. 2004. PMID: 15576286 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters